Form 13G's must be filed with the SEC upon any investor or entity amassing at least 5% of a company's outstanding shares, or alternatively, an investment falling beneath the 5...
Keep Reading →
February 12 - Hedge Funds, News
Individual investors might find hedge fund investing quite expensive, considering the 2-and-2o fee structure most hedge funds employ.
Keep Reading →
January 26 - Hedge Funds, News
In new filings with the U.S. Securities and Exchange Commission, Kelly Cardwell’s Central Square Management, James E.
Keep Reading →
January 5 - Hedge Funds, News
According to a recent filing with the SEC, Christopher Sackelton and Adam Grey's Coliseum Capital has acquired some 2.74 million shares of Universal Technical Institute, Inc...
Keep Reading →
December 15 - Hedge Funds, News
Deerfield Management, a healthcare-focused fund managed by James E.
Keep Reading →
December 11 - Hedge Funds, News
Federal funds future contracts suggest a 79% probability that the Federal Reserve will raise interest rates at the December policy meeting, an event which is expected to halt...
Keep Reading →
December 9 - Hedge Funds, News
A Schedule 13G is a public filing that must be submitted with the SEC by every hedge fund manager or other investor who acquires ownership of more than 5% in a publicly-traded...
Keep Reading →
December 1 - Hedge Funds, News
There are not many signals at the moment that suggest a continuation of the so-called “correction”, except for the potential letdown of the current earnings report season.
Keep Reading →
October 20 - Hedge Fund Analysis, Hedge Funds, News
Is it a good time to buy Alimera Sciences Inc (NASDAQ:ALIM)? James E.
Keep Reading →
October 15 - Hedge Funds, News
Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in three different healthcare...
Keep Reading →
October 13 - Hedge Funds, News
The U.S equities markets have seriously pulled back lately, so hedge funds and other investors are stumbling upon a greater number of quality investing opportunities.
Keep Reading →
September 23 - Hedge Funds, News
In a recent filing with the Securities and Exchange Commission (SEC), James E.
Keep Reading →
September 21 - Hedge Funds, News
James E. Flynn’s Deerfield Management has filed a Schedule 13G disclosing a 3.66% ownership stake in the newly public company Global Blood Therapeutics Inc.
Keep Reading →
August 19 - Hedge Funds, News
James E. Flynn’s Deerfield Management has filed a 13G with the U.S. Securities and Exchange Commission regarding its ownership of shares of Imprivata Inc. (NYSE:IMPR).
Keep Reading →
August 12 - Hedge Funds, News
James E. Flynn’s Deerfield Management disclosed that it has upped its position in Neos Therapeutics Inc.
Keep Reading →
July 29 - Hedge Funds, News
Constantly on the hunt for biotechnology stocks, James E. Flynn has identified another potential winner.
Keep Reading →
July 23 - Hedge Funds, News
Deerfield Management, led by James E. Flynn, has increased its stake in Streamline Health Solutions Inc. (NASDAQ:STRM). In a newly-amended 13G filing with the U.S.
Keep Reading →
July 14 - Hedge Funds, News
According to a recent filing with the Securities and Exchange Commission, James E. Flynn's Deerfield Management has acquired about 2.47 million shares of Healthways, Inc.
Keep Reading →
June 30 - Hedge Funds, News
Ken Griffin's (pictured) Citadel Investment Group has acquired about 1.09 million shares of 8Point3 Energy Partners LP (NASDAQ:CAFD).
Keep Reading →
June 29 - Hedge Funds, News
Following the initial public offering of Nivalis Therapeutics Inc (NASDAQ:NVLS) today, James E.
Keep Reading →
June 17 - Hedge Funds, News
According to a recent filing with the Securities and Exchange Commission, James E.
Keep Reading →
June 17 - Hedge Funds, News
James Flynn's Deerfield Management has filed its 13F with the SEC for the reporting period of March 31, with the investment manager disclosing a public equity portfolio valued...
Keep Reading →
May 29 - Hedge Funds, News
James E. Flynn's Deerfield Management is one of the funds that is focused on the healthcare sector, investing around 70% of its portfolio in healthcare stocks.
Keep Reading →
February 28 - Hedge Funds, News
James E. Flynn’s Deerfield Management entered a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) this week. According to the 13G Form filed with the U.S.
Keep Reading →
February 10 - Hedge Funds, News
James E. Flynn’s Deerfield Management recently increased its stake in Auspex Pharmaceuticals Inc (NASDAQ:ASPX) by 1.5 million shares at $56.5 per share.
Keep Reading →
February 2 - Hedge Funds, News
Kevin Kotler's Broadfin Capital and James Flynn's Deerfield Management have both initiated passive stakes in Alcobra Ltd (NASDAQ:ADHD).
Keep Reading →
January 20 - Hedge Funds, News
James Flynn’s Deerfield Management disclosed an increase in its stake in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) on Friday.
Keep Reading →
December 29 - Hedge Funds, News
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E.
Keep Reading →
November 3 - Hedge Funds, News
Mario Gabelli’s GAMCO Investors and James E.
Keep Reading →
October 27 - Hedge Funds, News
Pharmaceuticals and life sciences as a sector is where most of the money from hedge funds seems to be flowing in.
Keep Reading →
October 20 - Hedge Funds, News
In two new filings, Thomas E. Claugus' GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG).
Keep Reading →
October 16 - Hedge Funds, News, Tech
It seems the recent decline in Endologix, Inc. (NASDAQ:ELGX)’s stock by around 20% has made it more lucrative for hedge funds.
Keep Reading →
October 14 - Hedge Funds, News
Julian Baker and Felix Baker’s Baker Bros. Advisors is tightening its grip over XenoPort, Inc. (NASDAQ:XNPT) and so is James E.
Keep Reading →
October 13 - Hedge Funds, News
Two Schedule 13G forms filed with the SEC yesterday called my attention.
Keep Reading →
October 3 - Hedge Funds, News
Deerfield Management, managed by James E. Flynn, has disclosed upping its stake in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). A new filing with the U.S.
Keep Reading →
August 11 - Hedge Funds, News
James E. Flynn, the manager of Deerfield Management, has disclosed a new passive stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH). Mr.
Keep Reading →
July 1 - Hedge Funds, News
James E. Flynn's Deerfield Management reported a new stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Keep Reading →
April 30 - Hedge Funds, News
Deerfield Management, managed by James E. Flynn, has revealed raising its position in Trivascular Technologies Inc (NASDAQ:TRIV).
Keep Reading →
April 23 - Hedge Funds, News
As a new filing with the Securities and Exchange Commission showed, Deerfield Management, a healthcare focused investment firm, managed by James E.
Keep Reading →
April 16 - Hedge Funds, News
James E. Flynn, the manager of Deerfield Management, is still bullish on Streamline Health Solutions Inc. (NASDAQ:STRM).
Keep Reading →
April 7 - Hedge Funds, News
James E. Flynn, the manager of Deerfield Management, is bullish on Alphatec Holdings Inc (NASDAQ:ATEC).
Keep Reading →
March 31 - Hedge Funds, News
Deerfield Management, led by James E.
Keep Reading →
March 12 - Hedge Funds, News
James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported further raising its stake Auspex Pharmaceuticals Inc (NASDAQ:ASPX).
Keep Reading →
February 12 - Hedge Funds, News
James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported a position in Cara Therapeutics Inc. (NASDAQ:CARA).
Keep Reading →
February 10 - Hedge Funds, News
James E. Flynn's Deerfield Management has reported adding KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) to its equity portfolio.
Keep Reading →
February 6 - Hedge Funds, News
With four years remaining, Warren Buffett has a commanding lead in a decade-long bet that put a low-fee stock index fund up against a portfolio of high-priced hedge funds.
Keep Reading →
February 6 - Hedge Funds
James E. Flynn's Deerfield Management has revealed holding shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX), a company that went public today, on February 5.
Keep Reading →
February 5 - Hedge Funds, News
